EMEA-002631-PIP01-19-M01
Key facts
| Active substance |
Tapotoclax
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0123/2022
|
| PIP number |
EMEA-002631-PIP01-19-M01
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of acute myeloid leukaemia
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Amgen Europe B.V
Tel.: +44 (0)1223 420305 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|